Burning Rock Biotech Limited (BNR)
NASDAQ: BNR · Real-Time Price · USD
23.47
+0.99 (4.40%)
At close: Mar 10, 2026, 4:00 PM EDT
22.75
-0.72 (-3.07%)
After-hours: Mar 10, 2026, 4:55 PM EDT
Burning Rock Biotech Revenue
Burning Rock Biotech had revenue of 131.62M CNY in the quarter ending September 30, 2025, with 2.31% growth. This brings the company's revenue in the last twelve months to 539.28M, up 5.56% year-over-year. In the year 2024, Burning Rock Biotech had annual revenue of 515.82M, down -4.02%.
Revenue (ttm)
539.28M CNY
Revenue Growth
+5.56%
P/S Ratio
3.34
Revenue / Employee
800,111 CNY
Employees
674
Market Cap
252.69M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 515.82M | -21.61M | -4.02% |
| Dec 31, 2023 | 537.44M | -25.80M | -4.58% |
| Dec 31, 2022 | 563.24M | 55.38M | 10.90% |
| Dec 31, 2021 | 507.86M | 77.96M | 18.13% |
| Dec 31, 2020 | 429.90M | 48.23M | 12.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 824.50M |
| OPKO Health | 606.88M |
| Castle Biosciences | 344.23M |
| Fulgent Genetics | 322.67M |
| MDxHealth | 107.88M |
| FONAR | 106.03M |
| Prenetics Global | 92.39M |
| Biodesix | 88.50M |
BNR News
- 2 months ago - Burning Rock Announces Results of 2025 Annual General Meeting - GlobeNewsWire
- 3 months ago - Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025 - GlobeNewsWire
- 3 months ago - Burning Rock Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer - GlobeNewsWire
- 6 months ago - Burning Rock Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 9 months ago - Burning Rock Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 1 year ago - Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - Burning Rock Announces Results of 2024 Annual General Meeting - GlobeNewsWire